Coulter Partners places Hans T. Schambye as CEO of BOOST Pharma

BOOST Pharma is a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases. The Company’s lead program, BT‑101, is an allogeneic mesenchymal stem cell therapy for osteogenesis imperfecta, a severe rare bone disorder.

Hans Schambye is a highly regarded biotech entrepreneur and operator with a proven record in building and leading companies from drug discovery to late-stage clinical development and pivotal value-creating milestones. He has extensive expertise in operational leadership, clinical program management, company growth, and financing and investor strategy. Hans joins BOOST Pharma from Galecto Inc., where he served as President and CEO, leading the company through significant scientific, clinical, and financial milestones, and raising more than $500 million.

This leadership transition occurs at a strategically important time for BOOST Pharma, as it advances BT‑101, its lead cell‑therapy candidate for osteogenesis imperfecta (OI), a rare genetic disorder also known as Brittle Bone Disease.

Ingelise Saunders, Chair of BOOST Pharma, said: “Hans joined BOOST Pharma at a pivotal time for the Company. Having already made an impact as a member of our Board with his deep scientific insight and seasoned operational leadership, we are excited for him to step into the CEO role; he is the ideal fit to lead BOOST through its next phase of development.

“We are grateful to Coulter Partners for their work in identifying a leader of Hans’ caliber. Their ability to source high-level talent provided us with a natural and high-impact leadership solution as we advance our lead cell-therapy candidate.”

Nanna Soni, Client Partner at Coulter Partners, added: “We are delighted to have supported BOOST in the placement of Hans. We conducted a highly targeted search across Europe and focused on identifying a leader with a proven track record in leading and building a clinical stage company, to ensure the organization had access to the best possible expertise. Hans is an exceptional ‘drug hunter’ and operator – an MD, PhD who has led and scaled clinical stage biotechs – who is now on site in Denmark to drive the organization's corporate strategy and bring this breakthrough therapy closer to children in need.”

---

Dr. Hans T. Schambye, CEO BOOST Pharma

Hans currently serves as Chairperson of DANISH BIO and PreTT ApS and holds director positions at both BII and Tribune Therapeutics. His previous leadership roles include serving as CEO at ReceptIcon and Gastrotech Pharma A/S, as well as holding senior scientific and portfolio management positions at Maxygen in the United States. Hans also co-founded ProFound Pharma A/S, which was acquired by Maxygen, Inc.

Hans holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University. His early academic career at Stanford University and Copenhagen University produced foundational contributions in receptor biology.

About BOOST Pharma

About Coulter Partners